These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 22941182)

  • 1. Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature.
    Nashan B; Citterio F
    Transplantation; 2012 Sep; 94(6):547-61. PubMed ID: 22941182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
    Albano L; Berthoux F; Moal MC; Rostaing L; Legendre C; Genin R; Toupance O; Moulin B; Merville P; Rerolle JP; Bayle F; Westeel PF; Glotz D; Kossari N; Lefrançois N; Charpentier B; Blanc AS; Di Giambattista F; Dantal J;
    Transplantation; 2009 Jul; 88(1):69-76. PubMed ID: 19584683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients.
    Nashan B; Gaston R; Emery V; Säemann MD; Mueller NJ; Couzi L; Dantal J; Shihab F; Mulgaonkar S; Seun Kim Y; Brennan DC
    Transplantation; 2012 Jun; 93(11):1075-85. PubMed ID: 22683823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mammalian target of rapamycin (mTOR) inhibitors slow skin carcinogenesis, but impair wound healing.
    Feldmeyer L; Hofbauer GF; Böni T; French LE; Hafner J
    Br J Dermatol; 2012 Feb; 166(2):422-4. PubMed ID: 21895616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
    Diekmann F; Andrés A; Oppenheimer F
    Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
    Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M
    Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic approach to minimizing wound problems for de novo sirolimus-treated kidney transplant recipients.
    Tiong HY; Flechner SM; Zhou L; Wee A; Mastroianni B; Savas K; Goldfarb D; Derweesh I; Modlin C
    Transplantation; 2009 Jan; 87(2):296-302. PubMed ID: 19155988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients.
    Knight RJ; Villa M; Laskey R; Benavides C; Schoenberg L; Welsh M; Kerman RH; Podder H; Van Buren CT; Katz SM; Kahan BD
    Clin Transplant; 2007; 21(4):460-5. PubMed ID: 17645704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors.
    Jedlickova Z; Burlakova I; Bug G; Baurmann H; Schwerdtfeger R; Schleuning M
    Biol Blood Marrow Transplant; 2011 May; 17(5):657-63. PubMed ID: 20696263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus: efficacy and safety in cardiac transplantation.
    Schaffer SA; Ross HJ
    Expert Opin Drug Saf; 2010 Sep; 9(5):843-54. PubMed ID: 20701555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with everolimus is associated with a procoagulant state.
    Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ
    Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk evaluation and mitigation strategies: a focus on the mammalian target of rapamycin inhibitors.
    Gabardi S
    Prog Transplant; 2013 Mar; 23(1):55-7. PubMed ID: 23448821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?
    Zeier M; Van Der Giet M
    Transpl Int; 2011 Jan; 24(1):30-42. PubMed ID: 20642495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial.
    Dantal J; Berthoux F; Moal MC; Rostaing L; Legendre C; Genin R; Toupance O; Moulin B; Merville P; Rerolle JP; Bayle F; Westeel PF; Glotz D; Kossari N; Lefrançois N; Charpentier B; Quéré S; Di Giambattista F; Cassuto E;
    Transpl Int; 2010 Nov; 23(11):1084-93. PubMed ID: 20500493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can immunosuppressive strategies be used to reduce cancer risk in renal transplant patients?
    Geissler EK
    Transplant Proc; 2010 Nov; 42(9 Suppl):S32-5. PubMed ID: 21095449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growing experience with mTOR inhibitors in pediatric solid organ transplantation.
    Ganschow R; Pape L; Sturm E; Bauer J; Melter M; Gerner P; Höcker B; Ahlenstiel T; Kemper M; Brinkert F; Sachse MM; Tönshoff B
    Pediatr Transplant; 2013 Nov; 17(7):694-706. PubMed ID: 24004351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials.
    Pengel LH; Liu LQ; Morris PJ
    Transpl Int; 2011 Dec; 24(12):1216-30. PubMed ID: 21955006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus in clinical practice in long-term liver transplantation: an observational study.
    Casanovas T; Argudo A; Peña-Cala MC
    Transplant Proc; 2011; 43(6):2216-9. PubMed ID: 21839237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR inhibitors in pediatric kidney transplantation.
    Pape L; Ahlenstiel T
    Pediatr Nephrol; 2014 Jul; 29(7):1119-29. PubMed ID: 23740036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
    Somers MJ; Paul E
    J Clin Pharmacol; 2015 Apr; 55(4):368-76. PubMed ID: 25402866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.